Shanaz Sikder, MD
Endocrinology, Diabetes & Metabolism · Boise, IDNPI 1083980734
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,333 and has fallen 92.2% since, to $104 in 2025.
Across 104 payments — averaging $29.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$636
- Amgen$429
- Novo Nordisk$318
- Tandem Diabetes Care, Inc.$260
- AstraZeneca$253
- Corcept Therapeutics$202
- plus $975 from 15 others
What the payments were for
- Consulting fees$2007%
- Food & beverage$2,86693%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $636 |
| Amgen(2 entities) | 11 | $429 |
| Novo Nordisk | 18 | $318 |
| Tandem Diabetes Care, Inc. | 6 | $260 |
| AstraZeneca | 4 | $253 |
| Corcept Therapeutics | 8 | $202 |
| Neurocrine Biosciences, Inc. | 1 | $200 |
| Insulet Corporation | 5 | $154 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Sanofi-aventis U.S. LLC | 10 | $120 |
| Lilly USA, LLC | 8 | $107 |
| Medtronic(2 entities) | 5 | $83 |
| Antares Pharma, Inc. | 2 | $32 |
| Dexcom, Inc. | 2 | $30 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| BETA Bionics, Inc. | 1 | $23 |
| AbbVie | 1 | $19 |
| Pfizer | 1 | $18 |
| Bayer | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$232
- FREESTYLE LIBRE 3$158
- FreeStyle Libre$142
- Yorvipath$125
- Korlym$124
- FreeStyle Libre 2$120
- Repatha$114
- t:slim X2 Insulin Pump with Control-IQ$114
- Tresiba$107
- Prolia$102
How this compares
Too few endocrinology, diabetes & metabolism providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $73,009 |
| MounjaroTirzepatide | 24 | $41,875 |
| TrulicityDulaglutide | 18 | $28,942 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $23,302 |
| OzempicSemaglutide | 18 | $16,953 |
| JardianceEmpagliflozin | 17 | $12,342 |
| SynthroidLevothyroxine Sodium | 95 | $9,395 |
| Hydrocortisone | 125 | $9,375 |
| Cinacalcet Hcl | 12 | $8,449 |
| VascepaIcosapent Ethyl | 15 | $7,338 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $6,779 |
| Levothyroxine Sodium | 428 | $5,026 |
| Desmopressin AcetateDesmopressin (Nonrefrigerated) | 19 | $4,474 |
| Insulin Aspart FlexpenInsulin Aspart | 12 | $3,309 |
| HumalogInsulin Lispro | 15 | $3,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $107 | $74,10257 claims |
| Novo NordiskOzempic | $318 | $16,95318 claims |
| AbbVieSynthroid | $19 | $9,39595 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Boise
- Theodore RooseveltBoise$65K
- Julie FooteBoise$8K
- Richard ChristensenBoise$2K
- Robert MinnsBoise$644
- Robert EnnisMeridian$69K
- David LiljenquistIdaho Falls$9K
- Katy ConnleyEagle$6K
- Adam LykoPost Falls$5K
- Angelo CapricchioneBlackfoot$2K
- Michael HolyoakMeridian$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.